title: No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura.
authors: Giovanni
authors: G
authors: D'Arena
authors: Roberto
authors: R
authors: Guariglia
authors: Giovanna
authors: G
authors: Mansueto
authors: Maria Carmen
authors: MC
authors: Martorelli
authors: Giuseppe
authors: G
authors: Pietrantuono
authors: Oreste
authors: O
authors: Villani
authors: Rosa
authors: R
authors: Lerose
authors: Pellegrino
authors: P
authors: Musto
mesh_terms: D001565:Benzoates / Q000008:administration & dosage*; D002908:Chronic Disease; D004351:Drug Resistance; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000097:blood / Q000188:drug therapy*; D011720:Pyrazoles / Q000008:administration & dosage*; D011961:Receptors, Fc / Q000008:administration & dosage*; D053628:Receptors, Thrombopoietin / Q000819:agonists; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*; D016879:Salvage Therapy; D013926:Thrombopoietin / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D001565:Benzoates; D006834:Hydrazines; D011720:Pyrazoles; D011961:Receptors, Fc; D053628:Receptors, Thrombopoietin; D011993:Recombinant Fusion Proteins; C082218:MPL protein, human; D013926:Thrombopoietin; C488777:romiplostim; C520809:eltrombopag